Cleavage Stage, OvumNCT00710723
Vitrification Versus Slow Freezing of Human Day 3 Embryos
A study testing vitrification in people with Cleavage Stage, Ovum, run by University Hospital, Gasthuisberg at 1 site in Belgium.
Trial summary
In assisted reproduction technology (ART), cryopreservation of embryos maximizes the potential of IVF cycles. Currently different cryopreservation methods are used, the conventional slow freezing method and vitrification. Read more about this study
- Who is it for?
- Ages 18 to 43 yearsHealthy volunteers can take part
- Conditions the study is for
- Cleavage Stage, Ovum
- What is being tested?
- vitrification
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 901 participants
- Where
- 1 siteBelgium
- Study dates
- Oct 2005to Dec 2008
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 43 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Embryos of sufficient embryo quality: at least 6 cells on day 3 and less than 20 % fragmentation.
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country.
About this study
In assisted reproduction technology (ART), cryopreservation of embryos maximizes the potential of IVF cycles. Currently different cryopreservation methods are used, the conventional slow freezing method and vitrification. There is, therefore an immediate need to assess which cryopreservation technique is preferential in human IVF. In this prospective randomised study conventional slow freezing and vitrification, using the Hemi-straw carrier system, of human day 3 embryos were compared.
Read the detailed description
- Background Although there are studies that reported successful pregnancies after transfer of vitrified cleavage stage embryos, most of the studies focused on the vitrification of oocytes and blastocysts. As far as we know, there is only one report of a randomised prospective study were both common freezing methods -conventional slow freezing and vitrification (making use of the nylon loop system with 40% ethylene glycol), were compared for day 3 embryos (Rama Raju, Haranath et al., 2005). They report an implantation and pregnancy rate (14,9% and 35,0% respectively) with vitrification, which is significantly higher than the rates with the slow freezing protocol (4,2% and 17,4% respectively). There is still need to more randomised studies which compares both freezing methods for cleavage stage embryos . There is evidence in literature that the vitrification method used at LUFc (hemi-straw) is superior to the method used in the randomised trial of Rama Raju. Liebermann and Tucker compared both the hemi-straw and cryoloop system for vitrification of day 3 embryos derived from abnormally fertilized zygotes (Liebermann and Tucker, 2002). They found no statistical difference (p=0.07) in the survival rate, but the development after 24 hours was statistically better (p =0.002) using hemi-straws. Based on this study we would even expect better results than the study of Rama Raju. To further refine the effect of cryopreservation of cleavage stage embryos using the hemi-straw system on developmental and implantation potential, the effectiveness of vitrification (20% EG and 20% DMSO) was compared with slow freezing.
- Materials and methods
- Patients In this prospective study all patients underwent IVF or ICSI between are included. Fresh embryo transfer was carried out on day 3 after insemination. All surplus embryos who reached at least the 6 cell stage on day 3 and had less than 20% fragmentation were considered for cryopreservation using either vitrification or slow freezing.
- Randomisation All embryos will be cryopreserved by one of the two methods. Randomisation will take place at day 3 after insemination. For practical reasons, all embryos frozen on the same day will be randomly assigned to the same freezing method.
- Results from retrospective data analysis Vitrification has been used as a standard cryopreservation method at the LUFc since September 2004. So both slow freezing and vitrification had been used for cryopreservation of day 3 embryos. The method used depends on workload… so there was no randomisation. After a retrospective analysis of these data (124 cycles 43 in the slow group and 81 in the vitrification group), we noticed a significant increase in the survival of the embryos after vitrification (81.2% in the vitrification group versus 45.8% in the slow group; p<0.0001). There was no significant difference in pregnancy rate between both groups (19.8% in the vitrification versus 30.2% in slow group; p=NS). So far we saw a remarkable difference in survival immediately or 24h after thawing, but a clear difference in the implantation rate has not been discovered yet, therefore we would like to start a randomised trial to proof a significant difference at the implantation or pregnancy level.
- Vitrification of human embryos Our method was based on the procedure described by Vanderzwalmen et al 2000 (Vanderzwalmen, Bertin et al., 2000). First the embryos were equilibrated (PBS with 17% HSA ) for 2 min at room temperature. They were then transferred to the first vitrification solution (PBS + 14% HSA + 10% DMSO + 10% ethylene glycol) for 2 min at RT followed by 30 sec in the second vitrification solution (PBS + 12% HSA + 20 % DMSO + 20% ethylene glycol + ficoll + sucrose). Finally the embryos were loaded as quickly as possible on the Hemi-straw in a droplet of approximately 3 µl and immersed directly in liquid nitrogen. Afterwards the hemi-straw was inserted in the CBS-straw.
- Thawing after vitrification The hemi-straw holding exactly one embryo was pulled out of the CBS straw and immediately immersed into 3 ml of the first thawing solution (PBS with 20% HSA) for 3 min at 36°C. Afterwards the embryo was consecutively exposed for 2 min to the 3 other thawing solutions (0.5M sucrose, 0.25M sucrose and 0.125M sucrose respectively). The embryos were washed thoroughly and incubated overnight in COOK blastocyst medium. Embryos are considered as 'survived' if at least 50% of the blastomeres survived the vitrification procedure.
- Slow freezing and thawing procedure For the slow freezing and thawing procedure we used the HEPES-buffered commercial freezing medium of Cook (K-SICS 5000) with propandiol and sucrose as cryoprotectants.
- Statistical analysis and power calculation
Based on literature (Rama Raju et al 2005) we expect a 10 % higher implantation rate in the vitrification group (25%) versus the slow freezing group (15%)(Rama Raju, Haranath et al., 2005). To proof a significant difference at the implantation or pregnancy level with α=0,05 and a power (β) of 0,80. Therefore we would need 270 embryos transferred in each group.
- Conditions
- Cleavage Stage, Ovum
- Being tested
- vitrification
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
vitrificationProcedure or surgery
Vitrification using Hemi-straw carrier system.
| Study group | Role | What they receive |
|---|---|---|
| 1 | Experimental | vitrification Receives: Procedure: vitrification |
| 2 | No intervention | Slow freezing |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pregnancy rate
Measured: 9 months
Secondary outcomes (1)
survival rate after thawing of embryos
Measured: 24 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Jul 2008 (estimated)
- Study startOct 2005
- Study completionDec 2008 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cleavage Stage, OvumStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 901 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Gasthuisberg
- Sponsor type
- University, hospital or other
- Investigators
- D'Hooghe Thomas, Prof. Dr., Principal investigator, UZ Leuven
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00710723
- Sponsor's protocol ID
- dwille1
- Status last verified
- Jan 2008
- First submitted
- 4 Jan 2008
- Last updated
- 4 Jul 2008
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Jul 2008. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Vitrification Versus Slow Freezing of Human Day 3 Embryos
- ClinicalTrials.gov ID
- NCT00710723
- Acronym / sponsor ID
- dwille1
- Conditions
- Cleavage Stage, Ovum
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 901 participants (actual)
- Lead sponsor
- University Hospital, GasthuisbergUniversity, hospital or other
- Study start
- Oct 2005
- Study completion
- Dec 2008 (estimated)
- First posted
- 4 Jul 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In assisted reproduction technology (ART), cryopreservation of embryos maximizes the potential of IVF cycles. Currently different cryopreservation methods are used, the conventional slow freezing method and vitrification. There is, therefore an immediate need to assess which cryopreservation technique is preferential in human IVF. In this prospective randomised study conventional slow freezing and vitrification, using the Hemi-straw carrier system, of human day 3 embryos were compared.
Detailed description
- Background Although there are studies that reported successful pregnancies after transfer of vitrified cleavage stage embryos, most of the studies focused on the vitrification of oocytes and blastocysts. As far as we know, there is only one report of a randomised prospective study were both common freezing methods -conventional slow freezing and vitrification (making use of the nylon loop system with 40% ethylene glycol), were compared for day 3 embryos (Rama Raju, Haranath et al., 2005). They report an implantation and pregnancy rate (14,9% and 35,0% respectively) with vitrification, which is significantly higher than the rates with the slow freezing protocol (4,2% and 17,4% respectively). There is still need to more randomised studies which compares both freezing methods for cleavage stage embryos . There is evidence in literature that the vitrification method used at LUFc (hemi-straw) is superior to the method used in the randomised trial of Rama Raju. Liebermann and Tucker compared both the hemi-straw and cryoloop system for vitrification of day 3 embryos derived from abnormally fertilized zygotes (Liebermann and Tucker, 2002). They found no statistical difference (p=0.07) in the survival rate, but the development after 24 hours was statistically better (p =0.002) using hemi-straws. Based on this study we would even expect better results than the study of Rama Raju. To further refine the effect of cryopreservation of cleavage stage embryos using the hemi-straw system on developmental and implantation potential, the effectiveness of vitrification (20% EG and 20% DMSO) was compared with slow freezing.
- Materials and methods
- Patients In this prospective study all patients underwent IVF or ICSI between are included. Fresh embryo transfer was carried out on day 3 after insemination. All surplus embryos who reached at least the 6 cell stage on day 3 and had less than 20% fragmentation were considered for cryopreservation using either vitrification or slow freezing.
- Randomisation All embryos will be cryopreserved by one of the two methods. Randomisation will take place at day 3 after insemination. For practical reasons, all embryos frozen on the same day will be randomly assigned to the same freezing method.
- Results from retrospective data analysis Vitrification has been used as a standard cryopreservation method at the LUFc since September 2004. So both slow freezing and vitrification had been used for cryopreservation of day 3 embryos. The method used depends on workload… so there was no randomisation. After a retrospective analysis of these data (124 cycles 43 in the slow group and 81 in the vitrification group), we noticed a significant increase in the survival of the embryos after vitrification (81.2% in the vitrification group versus 45.8% in the slow group; p<0.0001). There was no significant difference in pregnancy rate between both groups (19.8% in the vitrification versus 30.2% in slow group; p=NS). So far we saw a remarkable difference in survival immediately or 24h after thawing, but a clear difference in the implantation rate has not been discovered yet, therefore we would like to start a randomised trial to proof a significant difference at the implantation or pregnancy level.
- Vitrification of human embryos Our method was based on the procedure described by Vanderzwalmen et al 2000 (Vanderzwalmen, Bertin et al., 2000). First the embryos were equilibrated (PBS with 17% HSA ) for 2 min at room temperature. They were then transferred to the first vitrification solution (PBS + 14% HSA + 10% DMSO + 10% ethylene glycol) for 2 min at RT followed by 30 sec in the second vitrification solution (PBS + 12% HSA + 20 % DMSO + 20% ethylene glycol + ficoll + sucrose). Finally the embryos were loaded as quickly as possible on the Hemi-straw in a droplet of approximately 3 µl and immersed directly in liquid nitrogen. Afterwards the hemi-straw was inserted in the CBS-straw.
- Thawing after vitrification The hemi-straw holding exactly one embryo was pulled out of the CBS straw and immediately immersed into 3 ml of the first thawing solution (PBS with 20% HSA) for 3 min at 36°C. Afterwards the embryo was consecutively exposed for 2 min to the 3 other thawing solutions (0.5M sucrose, 0.25M sucrose and 0.125M sucrose respectively). The embryos were washed thoroughly and incubated overnight in COOK blastocyst medium. Embryos are considered as 'survived' if at least 50% of the blastomeres survived the vitrification procedure.
- Slow freezing and thawing procedure For the slow freezing and thawing procedure we used the HEPES-buffered commercial freezing medium of Cook (K-SICS 5000) with propandiol and sucrose as cryoprotectants.
- Statistical analysis and power calculation
Based on literature (Rama Raju et al 2005) we expect a 10 % higher implantation rate in the vitrification group (25%) versus the slow freezing group (15%)(Rama Raju, Haranath et al., 2005). To proof a significant difference at the implantation or pregnancy level with α=0,05 and a power (β) of 0,80. Therefore we would need 270 embryos transferred in each group.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| 1 | Experimental | Procedure: vitrificationvitrification |
| 2 | No intervention | –Slow freezing |
Who may qualify
- Ages
- 18 to 43 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- Embryos of sufficient embryo quality: at least 6 cells on day 3 and less than 20 % fragmentation.
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| vitrificationVitrification using Hemi-straw carrier system. | Procedure or surgery | 1 |
Primary outcome
Pregnancy rate
Time frame: 9 months
1 secondary outcome
survival rate after thawing of embryos
Time frame: 24 hours
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Jul 2008.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
D'Hooghe Thomas, Prof. Dr. principal investigator
UZ Leuven
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing vitrification in people with Cleavage Stage, Ovum, run by University Hospital, Gasthuisberg at 1 site in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 4 Jul 2008. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pregnancy rate (time frame: 9 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Jul 2008.